Research programme: anti-apoptotic agents - MuriGen Therapeutics
Latest Information Update: 28 Aug 2020
At a glance
- Originator MuriGen Therapeutics
- Class
- Mechanism of Action Proto-oncogene protein c-bcl-2 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Inflammation; Thalassaemia; Thrombocytopenia
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Cancer in Australia
- 28 Aug 2020 No recent reports of development identified for preclinical development in Inflammation in Australia
- 28 Aug 2020 No recent reports of development identified for preclinical development in Thalassaemia in Australia